This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), provides $632,906 to Tulane University to conduct research on a novel role for the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The research aims to elucidate how AR's RNA-binding activity, rather than just its classical DNA-binding function, regulates the expression of key splicing factors that drive prostate cancer progression....
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $1,944,610.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding tumorigenesis and identifying therapeutic targets in CDK12-mutant prostate cancer. The research, which has a performance period from Apr 1, 2025 to Mar 31, 2028, involves a sub-award to the University of Texas MD Anderson Cancer...
This Project Grant award of $371,719 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the University of Pennsylvania to characterize epigenetic targets in prostate cancer. The key objectives are to: Gain mechanistic insights into how the histone methyltransferase NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex and enhance AR-driven transcription in prostate cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,079,624 to The Washington University in St. Louis to conduct research on the regulation of the androgen receptor (AR) by the long non-coding RNA NXTAR in prostate cancer. The research aims to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, synthesize PSMA-targeted nanoparticles with NXTAR-N5 oligonucleotide and small molecule inhibitors, and...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The $988,740 award, effective June 15, 2025 through June 14, 2028, will fund research by Weill Medical College of Cornell University to develop "Genomically Informed Morphological Stromal Signatures to Predict Lethal...
This $116,720 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will fund research to investigate the molecular basis of the interactions between the protein ABI1 and the androgen receptor (AR) in prostate cancer. The award will be used by the Research Foundation for the State University of New York, doing business as Upstate Medical Center, to conduct biophysical studies to elucidate how ABI1 binds to AR and affects its DNA binding properties. This research aims to provide a model for understanding how the ABI1-AR axis regulates transcription, which could inform the development of new inhibitors for prostate cancer treatment. The award period runs from December 1, 2024 to April 30, 2026.